Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baclofen, Roflumilast, Memantine, and Placebo in Fragile X Syndrome
NCT05418049Phase 2Active, not recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of baclofen, memantine and roflumilast in Fragile X syndrome (FXS) (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Change in EEG Relative Gamma Power. Started Sep 2022; status: active, not recruiting.
02
Drugs
baclofenmemantineroflumilast
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT05418049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418049.